Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, studies [44,45] have shown the increased risk of anemia due to relapses in no or low dose (0·25 mg/kg) of primaquine.”
In the citing paper
“Adherence to primaquine appeared to be high in the study, despite other studies reporting poor adherence and low effectiveness of unsupervised primaquine use [28].”
From Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study (2025) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bruxvoort, K., Goodman, C., Kachur, S. P., & Schellenberg, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084555 · Cited by 135 · cited 3×
“It is well recognized that the duration of antimalarial treatment is a critical determinant of adherence [9].”
BackgroundResultInfluential
Research works printed but not linked: 39
- K Thriemer, 2017, Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group, Malar J, 16, 141, 10.1186/s12936-017-1784-1 · DOI · Paper page
- JK Baird, 2004, Primaquine therapy for malaria, Clin Infect Dis, 39, 1336, 10.1086/424663 · DOI · Paper page
- GK John, 2012, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, Malar J, 11, 280, 10.1186/1475-2875-11-280 · DOI · Paper page
- W Maneeboonyang, 2011, Directly observed therapy with primaquine to reduce the recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border, Southeast Asian J Trop Med Public Health, 42, 9
- KP Grietens, 2010, Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon, Am J Trop Med Hyg, 82, 1017, 10.4269/ajtmh.2010.09-0521 · DOI
- R Takeuchi, 2010, Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border, Malar J, 9, 308, 10.1186/1475-2875-9-308 · DOI
- T Leslie, 2004, Compliance with 14-day primaquine therapy for radical cure of vivax malaria: a randomized placebo-controlled trial comparing unsupervised with supervised treatment, Trans R Soc Trop Med Hyg, 98, 168, 10.1016/S0035-9203(03)00041-5 · DOI · Paper page
- L von Seidlein, 2013, Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report, Malar J, 12, 112, 10.1186/1475-2875-12-112 · DOI · Paper page
- NM Anstey, 2012, Plasmodium vivax: Clinical Spectrum, Risk Factors and Pathogenesis, Adv Parasitol, 80, 151, 10.1016/B978-0-12-397900-1.00003-7 · DOI · Paper page
- NM Douglas, 2012, The anaemia of Plasmodium vivax malaria, Malar J, 11, 135, 10.1186/1475-2875-11-135 · DOI · Paper page
- NM Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in southern papua: a hospital-based surveillance study, PLoS Med, 10, e1001575, 10.1371/journal.pmed.1001575 · DOI · Paper page
- E Tjitra, 2008, Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia, PLoS Med, 5, e128, 10.1371/journal.pmed.0050128 · DOI · Paper page
- M Karyana, 2008, Epidemiology of multidrug resistant P. vivax and P. falciparum infection in Southern Papua, Indonesia, Malar J, 7, 148, 10.1186/1475-2875-7-148 · DOI
- Z Pava, 2016, Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia, PLoS ONE, 11, e0165340, 10.1371/journal.pone.0165340 · DOI
- A Ratcliff, 2007, Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison, Lancet, 369, 757, 10.1016/S0140-6736(07)60160-3 · DOI · Paper page
- KE Battle, 2014, Geographical variation in Plasmodium vivax relapse, Malar J, 13, 144, 10.1186/1475-2875-13-144 · DOI · Paper page
- A Ratcliff, 2007, Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in Southern Papua, Indonesia, Trans R Soc Trop Med Hyg, 101, 351, 10.1016/j.trstmh.2006.06.008 · DOI · Paper page
- E Tjitra, 2002, Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations, Antimicrob Agents Chemother, 46, 3947, 10.1128/AAC.46.12.3947-3953.2002 · DOI
- B Russell, 2008, Determinants of in vitro drug susceptibility testing of Plasmodium vivax, Antimicrob Agents Chemother, 52, 1040, 10.1128/AAC.01334-07 · DOI · Paper page
- RN Price, 2009, New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance, Curr Opin Infect Dis, 22, 430, 10.1097/QCO.0b013e32832f14c1 · DOI · Paper page
- RA Hutchinson, 2006, Malaria and deaths in the English marshes, Lancet, 367, 1947, 10.1016/S0140-6736(06)68850-8 · DOI
- NM Douglas, 2013, Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax, The Journal of infectious diseases
- R Noviyanti, 2015, Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination, PLoS Negl Trop Dis, 9, e0003739, 10.1371/journal.pntd.0003739 · DOI
- LJ Robinson, 2015, Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model, PLoS Med, 12, e1001891, 10.1371/journal.pmed.1001891 · DOI · Paper page
- T Abreha, 2017, Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial, PLoS Med, 14, e1002299, 10.1371/journal.pmed.1002299 · DOI · Paper page
- JW Bennett, 2013, Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria, The New England journal of medicine, 369, 1381, 10.1056/NEJMc1301936 · DOI · Paper page
- LD Bradford, 2002, CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants, Pharmacogenomics, 3, 229, 10.1517/14622416.3.2.229 · DOI · Paper page
- WE Collins, 1996, Primaquine resistance in Plasmodium vivax, Am J Trop Med Hyg, 55, 243, 10.4269/ajtmh.1996.55.243 · DOI · Paper page
- WC Cooper, 1953, Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria, Am J Trop Med Hyg, 2, 949, 10.4269/ajtmh.1953.2.949 · doi:10.4269/ajtmh.1953.2.949
- I Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia, Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
- PN Newton, 2010, Impact of poor-quality medicines in the 'developing' world, Trends in pharmacological sciences, 31, 99, 10.1016/j.tips.2009.11.005 · DOI · Paper page
- I Petralanda, 1995, Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region, Lancet, 345, 1433, 10.1016/S0140-6736(95)92620-8 · doi:10.1016/s0140-6736(95)92620-8
- MA Kron, 1996, Substandard primaquine phosphate for US Peace Corps personnel, Lancet, 348, 1453, 10.1016/S0140-6736(04)70101-4 · doi:10.1016/s0140-6736(04)70101-4
- JK Baird, 1995, Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia, Am J Trop Med Hyg, 52, 479, 10.4269/ajtmh.1995.52.479 · doi:10.4269/ajtmh.1995.52.479
- DJ Fryauff, 1995, Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria, Lancet, 346, 1190, 10.1016/S0140-6736(95)92898-7 · doi:10.1016/s0140-6736(95)92898-7
- AR Hasugian, 2007, Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria, Clin Infect Dis, 44, 1067, 10.1086/512677 · DOI · Paper page
- MT White, 2014, Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission, Elife, 3
- M Tanner, 2015, Malaria eradication and elimination: views on how to translate a vision into reality, BMC Med, 13, 167, 10.1186/s12916-015-0384-6 · DOI · Paper page
- A Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
Cited by
Plasmodium vivax in the Era of the Shrinking P. falciparum Map
Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K., & Mendis, K. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.03.009 · Cited by 269
Self-citationWatson, J., Taylor, W. R. J., Bancone, G., Chu, C. S., Jittamala, P., & White, N. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006440 · Cited by 77
Satyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Space–Time Clustering Characteristics of Malaria in Bhutan at the End Stages of Elimination
Wangdi, K., Penjor, K., Tobgyal, Lawpoolsri, S., Price, R. N., Gething, P. W., Gray, D. J., Da Silva Fonseca, E., & Clements, A. C. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115553 · Cited by 9
“vivax transmission in other parts of the world [32].”
BackgroundSelf-citationShifraw, T., Abdelmenan, S., Zewde, A., Worku, A., Abera, A., Mohammed, H., Etana, K., Keating, J., Chibsa, S., Girma, S., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05709-8
Self-citation
Metadata
- Authors
- Douglas, N. M., Poespoprodjo, J. R., Patriani, D., Malloy, M. J., Kenangalem, E., Sugiarto, P., Simpson, J. A., Soenarto, Y., Anstey, N. M., & Price, R. N.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-29
- Volume
- 14
- Issue
- 8
- Pages
- e1002379
- ISSN
- 1549-1676
- Cited by
- 107
- References
- 1
- Language
- en
- Funders
- Wellcome Trust (200909, 099875)
- National Health and Medical Research Council (1042072, 1104975, GNT1037304)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.